PedAM
Pediatric Disease Annotations & Medicines
| Disease | osteoporosis |
| Phenotype | C0376358|prostate cancer |
| Sentences | 24 |
| PubMedID- 25565887 | Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy. |
| PubMedID- 20201833 | osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem. |
| PubMedID- 24976229 | Objective: to estimate the risk of fracture (fracture risk assessment tool [frax] algorithm) because of the development of osteoporosis in prostate cancer patients undergoing androgen deprivation therapy (adt) for patients who would otherwise not have been identified for treatment by the t score. |
| PubMedID- 20332495 | Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. |
| PubMedID- 21050352 | osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem. |
| PubMedID- 20303574 | Zoledronic acid is a potent bisphosphonate that can prevent osteoporosis in patients with nonmetastatic (m0), prostate cancer (cap) who are initiating adt. |
| PubMedID- 24432249 | Denosumab was also studied for the prevention of osteoporosis in men with non-metastatic prostate cancer receiving androgen-deprivation therapy, which is associated with bone loss and fractures. |
| PubMedID- 21723763 | Vfa and addition of the 1/3 distal radius site performed by dxa both increased the rate of diagnosis and reduced the misclassification of osteoporosis in men with prostate cancer, compared with conventional dxa criteria alone. |
| PubMedID- 19901958 | Androgen-deprivation therapy (adt) for prostate cancer is associated with osteoporosis and fragility fractures. |
| PubMedID- 24340220 | Adt in men with prostate cancer leads to osteoporosis and vertebral fractures. |
| PubMedID- 26157638 | While these data are inconclusive, it does, nonetheless, raise concerns over the recommendation of dairy as a source of calcium for men at risk of developing osteoporosis, including those with prostate cancer who have had hormonal ablation treatment (malcolm et al., 2007). |
| PubMedID- 25636442 | Prevalence of osteoporosis in prostate cancer survivors ii: a meta-analysis of men not on androgen deprivation therapy. |
| PubMedID- 24269223 | By multivariate analysis, conducted to assess the significance of each variable affecting the development of osteoporosis in patients with prostate cancer, bone metastasis was found to be an independent predictor of osteoporosis (or 3.45, p = .002), along with bmi (continuous, or 0.75, p <.001). |
| PubMedID- 26451465 | Denosumab significantly reduced treatment-related osteoporosis associated with breast and prostate cancer and was superior to zoledronic acid in prevention or delaying of sre. |
| PubMedID- 23244490 | osteoporosis in patients with breast and prostate cancer: effect of disease and treatment modalities. |
| PubMedID- 23469798 | Conclusion: the endocrine therapies, particularly maximal androgen blockage, in patients with prostate cancer can be associated with anemia, osteoporosis, and ibs. |
| PubMedID- 25914556 | Antiresorptive therapy was expected to be a specific marker of bone metastases, although it can also be used to prevent osteoporosis among men with prostate cancer treated with hormonal therapy. |
| PubMedID- 22619678 | The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. |
| PubMedID- 26549995 | Aim: to assess the prevalence of metabolic syndrome (mets) and osteoporosis in patients with prostate cancer (pca) treated with radical radiotherapy (rt) with or without androgen deprivation therapy (adt). |
| PubMedID- 26217383 | This method is thought to be highly relevant to and representative of prostate cancer patients with osteoporosis undergoing therapeutic androgen deprivation. |
| PubMedID- 23098788 | So far no consensus guidelines have been published regarding the screening and treatment of osteoporosis in men with prostate cancer. |
| PubMedID- 22532777 | The promising outcomes in the initial trials with denosumab in treatment-related osteoporosis associated with breast and prostate cancer led to exploration of its use for the prevention of skeletal-related events in patients with solid tumors and bone metastasis, which is the focus of this review. |
| PubMedID- 24174178 | Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. |
| PubMedID- 23803126 | This systematic review was conducted to assess the efficacy and safety of bisphosphonates for prevention and treatment of osteopenia or osteoporosis in men with non-metastatic prostate cancer receiving androgen- deprivation therapy. |
Page: 1